brimonidine tartrate has been researched along with Disease Models, Animal in 54 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (5.56) | 18.2507 |
2000's | 20 (37.04) | 29.6817 |
2010's | 27 (50.00) | 24.3611 |
2020's | 4 (7.41) | 2.80 |
Authors | Studies |
---|---|
Hu, Y; Liu, J; Lou, X; Zhang, H; Zhao, Y | 1 |
Wu, J; Zhang, T; Zhou, X | 1 |
Kawamura, A; Kozai, S; Kunikane, E; Kurata, M; Shigemi, W; Shinno, K; Suzuki, G | 1 |
Cai, J; Li, L; Mao, Y; Song, Y; Wang, H; Xu, L | 1 |
Almazan, A; Andrews-Jones, L; Burke, J; Christie, LA; Engles, M; Ghosn, C; Kulkarni, A; López, FJ; Rajagopalan, L; Tamhane, M | 1 |
Jeong, SW; Jo, H; Kim, J; Kim, M; Park, HJ; Woo, YR | 1 |
Ciftci, F; Eyuboglu, S; Gumusel, A; Guzel, E; Marangoz, D; Seckin, I; Yalvac, I; Yilmaz, B | 1 |
Jiang, X; Li, X; Liu, Y; Lv, H; Wang, Y; Zhang, M | 1 |
Gil, D; Hsia, E; Tian, M | 1 |
Carr, BJ; Nguyen, CT; Stell, WK | 1 |
Diez-Alarcia, R; Horrillo, I; Meana, JJ; Ortega, JE; Urigüen, L | 1 |
Chindasub, P; Dai, Y; Duong-Polk, KX; Leung, CK; Lindsey, JD; Weinreb, RN | 1 |
Alvarez, T; Aubert, J; de Ménonville, ST; Jomard, A; Piwnica, D; Rosignoli, C; Roye, O; Schuppli Nollet, M | 1 |
Johnson, C; Krajnak, K; Miller, GR; Waugh, S | 1 |
Alarcón-Martínez, L; Bernal-Garro, JM; García-Ayuso, D; Jiménez-López, M; Nadal-Nicolás, FM; Nieto-López, L; Ortín-Martínez, A; Valiente-Soriano, FJ; Vidal-Sanz, M; Villegas-Pérez, MP; Wheeler, LA | 1 |
Agarwal, P; Agarwal, R; Ismail, NM; Kannan Kutty, M; Kapitonova, MY; Razali, N; Salmah Bakar, N; Smirnov, A | 1 |
Kitaoka, Y; Kojima, K; Munemasa, Y; Sase, K; Takagi, H | 1 |
Jang, I; Jeoung, JW; Kim, H; Kim, KE; Kim, YJ; Moon, H; Park, KH | 1 |
Díaz-DelCastillo, M; Galindo-Romero, C; Hallböök, F; Harun-Or-Rashid, M | 1 |
Arroba, AI; Beltramo, E; Hernández, C; Lopatina, T; Mazzeo, A; Porta, M; Simó, R; Valverde, AM | 1 |
Inada, K; Kawamura, A; Kozai, S; Kurokawa, K; Shinno, K; Tokushige, H | 1 |
Agey, P; Dong, CJ; Guo, Y; Hare, WA; Wheeler, L | 1 |
Jonas, JB; Ma, K; Pu, M; Xu, L; Zhang, H; Zhang, S | 1 |
Avraham-Lubin, BC; Cohen, Y; Dadon-Bar-El, S; Dratviman-Storobinsky, O; Goldenberg-Cohen, N; Hasanreisoglu, M; Weinberger, D | 1 |
Gul, M; Imrek, S; Ozdemir, G; Tolun, FI | 1 |
Campos, JG; Díaz, F; Moreno, M; Pérez de Vargas, I; Vidal, L; Villena, A | 1 |
Dermon, C; Panagis, L; Prokosch, V; Thanos, S; Volk, GF | 1 |
Bai, Y; Gil, DW; Kusari, J; Le, YZ; Padillo, E; Song, Z; Wang, J; Zhou, SX; Zhu, M | 1 |
Aktaş, S; Cağatay, H; Cumbul, A; Erdenöz, S; Eskicoğlu, E; Oba, E; Uslu, U; Yiğit, U | 1 |
Pinar-Sueiro, S; Rivas, MA; Urcola, H; Vecino, E | 1 |
Bhagav, P; Chandran, S; Upadhyay, H | 1 |
Aburahma, MH; Mahmoud, AA | 1 |
Alba-Delgado, C; Berrocoso, E; Borges, G; Horrillo, I; Meana, JJ; Mico, JA; Neto, F; Ortega, JE; Sánchez-Blázquez, P | 1 |
Chen, DF; Chen, H; Cho, KS; Guo, W; Luo, G; Pang, IH; Wang, WH; Yang, Q; Yu, D | 1 |
Chang, TH; Chen, FA; Chien, ST; Horng, CT; Kao, WT; Tsai, MK; Tsai, ML | 1 |
Naskar, R; Quinto, K; Schuettauf, F; Zurakowski, D | 1 |
Cai, JJ; Haynes, WG; Lee, HC; Martins, JB; Morgan, DA | 1 |
Gendron, ME; Perrault, LP; Thorin, E | 1 |
Dong, RG; Flavahan, NA; Flavahan, S; Krajnak, K; Welcome, D | 1 |
Aloni, E; Bakalash, S; Ben Simon, GJ; Rosner, M | 1 |
Kamata, K; Kobayashi, T; Matsumoto, T | 1 |
Alcala, SR; Danylkova, NO; McLoon, LK; Pomeranz, HD | 1 |
Hallböök, F; Lafuente, M; Lindqvist, N; Lönngren, U; Mayor, S; Näpänkangas, U; Vidal-Sanz, M | 1 |
Aktaş, Z; Akyürek, N; Gürelik, G; Hasanreisoğlu, B; Onol, M | 1 |
Avni, I; Barak, A; Ben-Shoshan, J; George, J; Levkovitch-Verbin, H; Luboshits, G; Rosner, M; Schwartz, S; Ziv, H | 1 |
Hernández, M; Urcola, JH; Vecino, E | 1 |
de Villiers, AS; Jaffer, A; Russell, VA; Sagvolden, T; Searson, A; Taljaard, JJ | 1 |
Schwartz, M; Wheeler, LA; Yoles, E | 1 |
Edward, DP; Lark, KK; Pasha, AS; Yan, X | 1 |
Allie, S; Russell, V; Wiggins, T | 1 |
Lagrèze, WA | 1 |
Ahmed, FA; Chaudhary, P; Hegazy, K; Sharma, SC | 1 |
Grehn, F | 1 |
Benozzi, J; Campanelli, JL; Nahum, LP; Rosenstein, RE | 1 |
54 other study(ies) available for brimonidine tartrate and Disease Models, Animal
Article | Year |
---|---|
Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury.
Topics: Animals; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen Peroxide; Indoles; Macrophages; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Nitric Oxide Synthase Type II; Optic Nerve Injuries; Polymers; Reactive Oxygen Species; Retina; Retinal Degeneration; Retinal Ganglion Cells; Transcriptome | 2021 |
Brimonidine enhances inhibitory postsynaptic activity of OFF- and ON-type retinal ganglion cells in a Wistar rat chronic glaucoma model.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Chronic Disease; Disease Models, Animal; Excitatory Postsynaptic Potentials; Glaucoma; Intraocular Pressure; Male; Membrane Potentials; Patch-Clamp Techniques; Presynaptic Terminals; Rats; Rats, Wistar; Retinal Ganglion Cells; Synaptic Transmission | 2019 |
Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Animals; Aqueous Humor; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Chromatography, High Pressure Liquid; Disease Models, Animal; Drug Compounding; Drug Therapy, Combination; Glaucoma; Male; Ophthalmic Solutions; Rabbits; Sulfonamides; Tandem Mass Spectrometry; Thiazines; Vitreous Body | 2021 |
Neuroprotective Effect of Brimonidine against Facial Nerve Crush Injury in Rats via Suppressing GFAP/PAF Activation and Neuroinflammation.
Topics: Animals; Brimonidine Tartrate; Crush Injuries; Disease Models, Animal; Facial Nerve; Facial Nerve Injuries; Mice; Neuroinflammatory Diseases; Neuroprotective Agents; Rats; Rats, Wistar | 2021 |
A nonhuman primate model of blue light-induced progressive outer retina degeneration showing brimonidine drug delivery system-mediated cyto- and neuroprotection.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Choroid; Cytoprotection; Disease Models, Animal; Drug Delivery Systems; Electroretinography; Fluorescein Angiography; Fundus Oculi; Geographic Atrophy; Macaca fascicularis; Neuroprotection; Ophthalmic Solutions; Retinal Photoreceptor Cell Outer Segment; Retinal Pigment Epithelium; Tomography, Optical Coherence; Visual Acuity | 2021 |
Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel.
Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Animals; Antimicrobial Cationic Peptides; Brimonidine Tartrate; Cathelicidins; Cell Movement; Disease Models, Animal; Enzyme Induction; Enzymes; Female; Gels; Mast Cells; Mice; RNA, Messenger; Rosacea | 2017 |
Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells.
Topics: Animals; Antioxidants; Apoptosis; Brimonidine Tartrate; Disease Models, Animal; Glaucoma; Intraocular Pressure; Male; Melatonin; Neuroprotective Agents; Rats; Rats, Wistar; Retinal Ganglion Cells; Tonometry, Ocular | 2018 |
α-adrenergic agonist brimonidine control of experimentally induced myopia in guinea pigs: A pilot study.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Disease Models, Animal; Drug Therapy, Combination; Guinea Pigs; Intraocular Pressure; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Pilot Projects; Pirenzepine; Refractive Errors | 2017 |
Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Calcium; Disease Models, Animal; Erythema; HEK293 Cells; Humans; Male; Mice; Mice, Hairless; Oxymetazoline; Prazosin; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Rosacea; Ultraviolet Rays; Vasoconstriction; Yohimbine | 2018 |
Alpha
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Axial Length, Eye; Brimonidine Tartrate; Chickens; Clonidine; Disease Models, Animal; Guanfacine; Intravitreal Injections; Male; Myopia; Sensory Deprivation; Yohimbine | 2019 |
Chronic fluoxetine reverses the effects of chronic corticosterone treatment on α
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic Neurons; Animals; Antidepressive Agents, Second-Generation; Brimonidine Tartrate; Cell Body; Corticosterone; Dendrites; Disease Models, Animal; Fluoxetine; Guanosine 5'-O-(3-Thiotriphosphate); Hypothalamo-Hypophyseal System; In Vitro Techniques; Isoquinolines; Locus Coeruleus; Male; Microdialysis; Naphthyridines; Norepinephrine; Pituitary-Adrenal System; Prefrontal Cortex; Presynaptic Terminals; Rats; Receptors, Adrenergic, alpha-2; Stress, Psychological; Sulfur Radioisotopes | 2019 |
Brimonidine protects against loss of Thy-1 promoter activation following optic nerve crush.
Topics: Adrenergic alpha-2 Receptor Agonists; Analysis of Variance; Animals; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Female; Longitudinal Studies; Male; Mice; Microscopy, Fluorescence; Nerve Crush; Optic Nerve Injuries; Promoter Regions, Genetic; Protective Agents; Quinoxalines; Retinal Ganglion Cells; Thy-1 Antigens | 2013 |
Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Inflammatory Agents; Biopsy; Brimonidine Tartrate; Disease Models, Animal; Female; Humans; Inflammation; Mice, Inbred BALB C; Quinoxalines; Receptors, Adrenergic, alpha-2; Skin; Tissue Culture Techniques; Vasoconstrictor Agents; Vasodilation | 2014 |
Recovery of vascular function after exposure to a single bout of segmental vibration.
Topics: Acetylcholine; Animals; Arteries; Brimonidine Tartrate; Disease Models, Animal; Endothelium, Vascular; Male; Quinoxalines; Rats; Rats, Sprague-Dawley; Time Factors; Vasoconstriction; Vibration | 2014 |
A novel in vivo model of focal light emitting diode-induced cone-photoreceptor phototoxicity: neuroprotection afforded by brimonidine, BDNF, PEDF or bFGF.
Topics: Animals; Brain-Derived Neurotrophic Factor; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Electronics; Eye Proteins; Female; Fibroblast Growth Factor 2; Light; Nerve Growth Factors; Neuroprotective Agents; Quinoxalines; Rats, Sprague-Dawley; Retinal Cone Photoreceptor Cells; Serpins; Time Factors; Tomography, Optical Coherence | 2014 |
Anterior and posterior segment changes in rat eyes with chronic steroid administration and their responsiveness to antiglaucoma drugs.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Catalase; Dexamethasone; Disease Models, Animal; Female; Glutathione; Intraocular Pressure; Latanoprost; Male; Ocular Hypertension; Oxidative Stress; Pilocarpine; Prostaglandins F, Synthetic; Quinoxalines; Rats, Sprague-Dawley; Retina; Sulfonamides; Superoxide Dismutase; Thiophenes; Timolol | 2015 |
Axonal protection by brimonidine with modulation of p62 expression in TNF-induced optic nerve degeneration.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Axons; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Heat-Shock Proteins; Immunoblotting; Immunoenzyme Techniques; Intravitreal Injections; Male; Nerve Degeneration; Optic Nerve Diseases; Rats; Rats, Wistar; Sequestosome-1 Protein; Tumor Necrosis Factor-alpha | 2015 |
Neuroprotective Effects of Human Serum Albumin Nanoparticles Loaded With Brimonidine on Retinal Ganglion Cells in Optic Nerve Crush Model.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Drug Carriers; Humans; Immunohistochemistry; Intravitreal Injections; Male; Nanoparticles; Nerve Crush; Optic Nerve; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Serum Albumin | 2015 |
Alpha2-Adrenergic-Agonist Brimonidine Stimulates Negative Feedback and Attenuates Injury-Induced Phospho-ERK and Dedifferentiation of Chicken Müller Cells.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Blotting, Western; Brimonidine Tartrate; Cell Dedifferentiation; Cells, Cultured; Chickens; Disease Models, Animal; Ependymoglial Cells; Immunohistochemistry; MAP Kinase Signaling System; Retina; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2015 |
Effects of the neuroprotective drugs somatostatin and brimonidine on retinal cell models of diabetic retinopathy.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Humans; Male; Microvessels; Neuroprotective Agents; Pericytes; Rats; Receptors, Somatostatin; Retina; Retinal Neurons; Somatostatin; Vascular Endothelial Growth Factor A | 2016 |
The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Topics: Administration, Topical; Animals; Antihypertensive Agents; Brimonidine Tartrate; Chromatography, Liquid; Disease Models, Animal; Glaucoma; Male; Melanins; Ophthalmic Solutions; Rabbits; Retina; Tandem Mass Spectrometry; Vitreous Body | 2017 |
Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Calcium; Calcium Signaling; Disease Models, Animal; Excitatory Amino Acid Agonists; Glaucoma; Male; N-Methylaspartate; Neuroprotective Agents; Patch-Clamp Techniques; Phosphodiesterase Inhibitors; Quinoxalines; Rabbits; Rats; Rats, Inbred BN; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, N-Methyl-D-Aspartate; Retina; Retinal Ganglion Cells; Rolipram | 2008 |
Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Survival; Disease Models, Animal; Injections, Intraperitoneal; Nerve Crush; Neuroprotective Agents; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells | 2009 |
Possible neuroprotective effect of brimonidine in a mouse model of ischaemic optic neuropathy.
Topics: Animals; Brimonidine Tartrate; Disease Models, Animal; Eye Proteins; Fluorescent Antibody Technique, Indirect; Gene Expression; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Heme Oxygenase-1; Hypoxia-Inducible Factor 1, alpha Subunit; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factors; Neuroprotective Agents; Nitric Oxide Synthase Type III; Optic Neuropathy, Ischemic; Oxidative Stress; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, TIE-2; Retinal Ganglion Cells; Retinal Neovascularization; Serpins; Superoxide Dismutase; Superoxide Dismutase-1; Vascular Endothelial Growth Factor A | 2009 |
Retinal oxidative stress induced by intraocular hypertension in rats may be ameliorated by brimonidine treatment and N-acetyl cysteine supplementation.
Topics: Acetylcysteine; Animals; Brimonidine Tartrate; Catalase; Disease Models, Animal; Drug Therapy, Combination; Glutathione Peroxidase; Hyaluronic Acid; Intraocular Pressure; Male; Malondialdehyde; Nitric Oxide; Ocular Hypertension; Oxidative Stress; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Diseases; Tonometry, Ocular | 2009 |
Reaction of Müller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Disease Models, Animal; Glaucoma; Glial Fibrillary Acidic Protein; Gliosis; Intraocular Pressure; Latanoprost; Male; Neuroglia; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Wistar; Retina; Timolol; Tonometry, Ocular | 2010 |
Alpha2-adrenergic receptors and their core involvement in the process of axonal growth in retinal explants.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Autoradiography; Axons; Brimonidine Tartrate; Clonidine; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Fluorescent Antibody Technique, Indirect; Glaucoma; Glial Fibrillary Acidic Protein; Optic Nerve Injuries; Organ Culture Techniques; Platelet Activating Factor; Protein Disulfide-Isomerases; Proteomics; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Laminin; Retina; Retinal Degeneration; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Effect of brimonidine on retinal and choroidal neovascularization in a mouse model of retinopathy of prematurity and laser-treated rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Choroidal Neovascularization; Disease Models, Animal; Dose-Response Relationship, Drug; Fibroblast Growth Factor 2; Fluorescein Angiography; Humans; Immunoblotting; Infant, Newborn; Intravitreal Injections; Laser Coagulation; Male; Mice; Mice, Inbred C57BL; Oxygen; Quinoxalines; Rabbits; Rats; Rats, Inbred BN; Retinal Neovascularization; Retinopathy of Prematurity; Time Factors | 2011 |
An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury.
Topics: Animals; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Hyperbaric Oxygenation; Immunohistochemistry; Injections, Intravenous; Memantine; Neuroprotective Agents; Ophthalmic Solutions; Quinoxalines; Rats; Rats, Wistar; Reperfusion Injury; Retina; Retinal Ganglion Cells | 2011 |
Prevention of retinal ganglion cell swelling by systemic brimonidine in a rat experimental glaucoma model.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glaucoma, Open-Angle; Injections, Intraperitoneal; Intraocular Pressure; Papilledema; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Treatment Outcome | 2011 |
Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation.
Topics: Acrylic Resins; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Chemistry, Pharmaceutical; Delayed-Action Preparations; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Glaucoma; Hydrogen-Ion Concentration; Intraocular Pressure; Kinetics; Nanoparticles; Nanotechnology; Quinoxalines; Rabbits; Solubility; Technology, Pharmaceutical | 2011 |
Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation.
Topics: Absorbable Implants; Acrylic Resins; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Alginates; Animals; Brimonidine Tartrate; Calorimetry, Differential Scanning; Cellulose; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Compounding; Glaucoma; Glucuronic Acid; Hexuronic Acids; Hydrophobic and Hydrophilic Interactions; Hypromellose Derivatives; Intraocular Pressure; Kinetics; Methylcellulose; Ophthalmic Solutions; Polymers; Polymethacrylic Acids; Polyvinyls; Povidone; Quinoxalines; Rabbits; Solubility; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; X-Ray Diffraction | 2011 |
The function of alpha-2-adrenoceptors in the rat locus coeruleus is preserved in the chronic constriction injury model of neuropathic pain.
Topics: Action Potentials; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Brimonidine Tartrate; Clonidine; Desipramine; Disease Models, Animal; Idazoxan; Locus Coeruleus; Male; MAP Kinase Signaling System; Medulla Oblongata; Neuralgia; Norepinephrine; Prefrontal Cortex; Quinoxalines; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Signal Transduction; Spinal Cord | 2012 |
Microbead-induced ocular hypertensive mouse model for screening and testing of aqueous production suppressants for glaucoma.
Topics: Animals; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Disease Models, Animal; Drug Evaluation, Preclinical; Feasibility Studies; Intraocular Pressure; Latanoprost; Mice; Mice, Inbred C57BL; Microspheres; Muscarinic Agonists; Ocular Hypertension; Optic Nerve; Pilocarpine; Prostaglandins F, Synthetic; Quinoxalines; Retinal Ganglion Cells; Sulfonamides; Thiazines; Timolol; Tomography, Optical Coherence | 2012 |
The activity of lowering intraocular pressure of cassiae seed extract in a DBA/2J mouse glaucoma model.
Topics: Acetazolamide; Animals; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Cassia; Chromatography, High Pressure Liquid; Disease Models, Animal; Glaucoma; Glycosides; Intraocular Pressure; L-Lactate Dehydrogenase; Male; Mice; Mice, Inbred DBA; Plant Extracts; Polyphenols; Quinoxalines; Seeds | 2013 |
Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model.
Topics: Aging; Analysis of Variance; Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Glaucoma; Memantine; Mice; Mice, Inbred DBA; Quinoxalines; Retinal Ganglion Cells; Timolol | 2002 |
Alpha 2-Adrenergic stimulation is protective against ischemia-reperfusion-induced ventricular arrhythmias in vivo.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Brimonidine Tartrate; Disease Models, Animal; Electrocardiography; Female; Heart Rate; Kidney; Male; Myocardial Ischemia; Myocardial Reperfusion; Quinoxalines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sympathetic Nervous System; Tachycardia, Ventricular; Ventricular Fibrillation | 2002 |
Loss of endothelial KATP channel-dependent, NO-mediated dilation of endocardial resistance coronary arteries in pigs with left ventricular hypertrophy.
Topics: Adenosine Triphosphate; Animals; Bradykinin; Brimonidine Tartrate; Canada; Charybdotoxin; Coronary Vessels; Disease Models, Animal; Drug Therapy, Combination; Endocardium; Endothelium, Vascular; Glyburide; Guanylate Cyclase; Hemodynamics; Hypertrophy, Left Ventricular; Indomethacin; Male; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; Nitroprusside; Oxadiazoles; Potassium Channels; Quinoxalines; Swine; Vascular Resistance; Vasodilation | 2004 |
Acute vibration increases alpha2C-adrenergic smooth muscle constriction and alters thermosensitivity of cutaneous arteries.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Arteries; Body Temperature Regulation; Brimonidine Tartrate; Cold Temperature; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Muscle, Smooth, Vascular; Neuromuscular Diseases; Quinolizines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Skin; Tail; Vasoconstriction; Vibration | 2006 |
A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy.
Topics: Acute Disease; Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Dizocilpine Maleate; Glatiramer Acetate; Immunization; Injections; Intraocular Pressure; Male; Neuroprotective Agents; Ocular Hypertension; Optic Nerve Diseases; Peptides; Quinoxalines; Rats; Rats, Inbred Lew; Retinal Ganglion Cells; Vaccination | 2006 |
Mechanisms underlying lysophosphatidylcholine-induced potentiation of vascular contractions in the Otsuka Long-Evans Tokushima Fatty (OLETF) rat aorta.
Topics: Animals; Aorta, Thoracic; Brimonidine Tartrate; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Lysophosphatidylcholines; Male; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Potassium; Protein Kinase Inhibitors; Protein Tyrosine Phosphatases; Quinoxalines; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Receptors, G-Protein-Coupled; RNA, Messenger; Up-Regulation; Vanadates; Vasoconstriction; Vasoconstrictor Agents | 2006 |
Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy.
Topics: Adrenergic alpha-Agonists; Animals; Axons; Benzoxazines; Brimonidine Tartrate; Cell Survival; Coloring Agents; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Neuroprotective Agents; Ophthalmic Solutions; Optic Neuropathy, Ischemic; Oxazines; Quinoxalines; Rats; Rats, Long-Evans; Retinal Ganglion Cells | 2007 |
The growth factor response in ischemic rat retina and superior colliculus after brimonidine pre-treatment.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Axons; Brain Ischemia; Brimonidine Tartrate; Cytoprotection; Disease Models, Animal; Gene Expression Regulation; Intercellular Signaling Peptides and Proteins; Male; Nerve Degeneration; Neuroprotective Agents; Optic Nerve; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Growth Factor; Retinal Ganglion Cells; RNA, Messenger; Superior Colliculi; Up-Regulation | 2006 |
Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Apoptosis; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Endothelin-1; Infusion Pumps, Implantable; Neuroprotective Agents; Optic Neuropathy, Ischemic; Quinoxalines; Rabbits; Retina; Retinal Ganglion Cells | 2007 |
Drug modification of angiogenesis in a rat cornea model.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Corneal Neovascularization; Corneal Stroma; Disease Models, Animal; Drug Implants; Fibroblast Growth Factor 2; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Wistar; Sulfonamides; Thiophenes; Timolol | 2008 |
Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Intraocular Pressure; Latanoprost; Neuroprotective Agents; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells | 2008 |
Alpha 2-adrenoceptor mediated inhibition of [3H]dopamine release from nucleus accumbens slices and monoamine levels in a rat model for attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antihypertensive Agents; Attention Deficit Disorder with Hyperactivity; Biogenic Monoamines; Brimonidine Tartrate; Disease Models, Animal; Dopamine; Hypertension; In Vitro Techniques; Male; Neurons; Norepinephrine; Nucleus Accumbens; Quinoxalines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Adrenergic, alpha-2; Tritium | 1995 |
Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration.
Topics: Action Potentials; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Axons; Brimonidine Tartrate; Cell Count; Cell Survival; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Nerve Degeneration; Neuroprotective Agents; Optic Nerve; Optic Nerve Diseases; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Retinal Ganglion Cells; Timolol; Yohimbine | 1999 |
The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Division; Conjunctiva; Disease Models, Animal; Fibroblasts; Glaucoma; Intraocular Pressure; Latanoprost; Microfilament Proteins; Ophthalmic Solutions; Proliferating Cell Nuclear Antigen; Prostaglandins F, Synthetic; Quinoxalines; Rabbits | 1999 |
Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder--the spontaneously hypertensive rat.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Brimonidine Tartrate; Disease Models, Animal; Dopamine; Down-Regulation; Hypertension; Idazoxan; In Vitro Techniques; Male; Models, Neurological; Norepinephrine; Prefrontal Cortex; Quinoxalines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Long-Evans; Receptors, Adrenergic, alpha-2 | 2000 |
[Neuroprotection. Bases and possibilities of a future clinical use].
Topics: Adrenergic alpha-Agonists; Animals; Apoptosis; Brimonidine Tartrate; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Eye Diseases; Forecasting; Glaucoma; Humans; Memantine; Neuroprotective Agents; Optic Neuritis; Quinoxalines; Retinal Diseases; Visual Fields | 2001 |
Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure.
Topics: Adrenergic alpha-Antagonists; Age Factors; Animals; Brimonidine Tartrate; Cell Count; Cell Survival; Disease Models, Animal; Female; Glaucoma; Intraocular Pressure; Nerve Degeneration; Neuroprotective Agents; Quinoxalines; Rats; Rats, Wistar; Retinal Ganglion Cells; Time Factors | 2001 |
[Prospects for neuroprotective glaucoma therapy].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; Betaxolol; Brain-Derived Neurotrophic Factor; Brimonidine Tartrate; Calcium Channel Blockers; Disease Models, Animal; Dopamine Agents; Glaucoma; Glaucoma, Open-Angle; Haplorhini; Humans; Memantine; Neuroprotective Agents; Nimodipine; Nitric Oxide Synthase; Quinoxalines; Receptors, N-Methyl-D-Aspartate | 2001 |
Effect of hyaluronic acid on intraocular pressure in rats.
Topics: Animals; Anterior Chamber; Antihypertensive Agents; Brimonidine Tartrate; Disease Models, Animal; Hyaluronic Acid; Injections; Intraocular Pressure; Latanoprost; Male; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Wistar; Timolol; Tonometry, Ocular | 2002 |